Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: J. Michael Dixon, MD

Click on the topic below for comments by Dr J. Michael Dixon to comment on. You will also find links to related articles and clinical trials.

Breast cysts as a cancer risk factor
Biochemistry of breast cysts
Intratumoral estrogen levels in breast cancer
Neoadjuvant endocrine therapy
Response rates with neoadjuvant endocrine therapy
Time to response with neoadjuvant endocrine therapy
Randomized trials of neoadjuvant Arimidex
Response criteria with neoadjuvant therapy
Biologic effect of endocrine agents
Combining endocrine agents
Quality of life with neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy of locally advanced breast cancer
Neoadjuvant therapy of inflammatory breast cancer
Neoadjuvant therapy of elderly patients
Timing of surgery after neoadjuvant therapy
Neoadjuvant therapy with aromatase inhibitors

Timing of surgery after neoadjuvant therapy

Play Audio Below:

In those patients who respond well by three months but still have large tumors in a number of those you would end by six months being able to operate them and do the surgery you want.

Also, some patients are still reluctant about surgery, and part of being a doctor is to treat patients as an individual and some patients come not wanting surgery at all. They take the drugs, by three months their tumor is smaller, they come around by six months they say, "Well, it has gotten much smaller. Yes, okay. Now, you can operate now and that’s fine." It’s part of building a relationship with the patient so that they trust you. I think one of the very important issues and there’s a 1% percent mortality in most published series have been mastectomy and axillary dissection on women over the age 70. It’s not because the surgeons kill a patient. It’s because the surgery is pretty stressful, it’s a longer operation and there’s potential for more complications. So, by doing less surgery, you have less chance of the patient dying of MI, stroke and getting complications such as hematomas. I think there’s another issue really – the morbidity of having a slightly bigger and longer operation.

Relevant Articles:

Timing of surgery with regard to the menstrual cycle in women with primary breast cancer. [Review] Badwe RA. Mittra I. Havaldar R. Surgical Clinics of North America. 79(5):1047-59, 1999.

Top of Page

Home · Contact us
Terms of use and general disclaimer